scroll to top
0

EBSCO Auth Banner

Let's find your institution. Click here.

Clinicopathological characteristics and survival outcomes of male breast cancer according to race: A SEER population-based study.

  • Academic Journal
  • Sun HF; Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Collaborative Innovation Center of Cancer Medicine, Fudan University Shanghai Cancer Center, Shanghai, 200030, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200030, China.
    Zhao Y; Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Collaborative Innovation Center of Cancer Medicine, Fudan University Shanghai Cancer Center, Shanghai, 200030, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200030, China.
    Gao SP; Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Collaborative Innovation Center of Cancer Medicine, Fudan University Shanghai Cancer Center, Shanghai, 200030, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200030, China.
    Li LD; Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Collaborative Innovation Center of Cancer Medicine, Fudan University Shanghai Cancer Center, Shanghai, 200030, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200030, China.
    Fu WY; Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Collaborative Innovation Center of Cancer Medicine, Fudan University Shanghai Cancer Center, Shanghai, 200030, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200030, China.
    Jiang HL; Division of Molecular Medicine and Genetic, Department of Internal Medicine and Life Sciences Insititute, University of Michigan, Ann Abor, Michgan 48109, USA.
    Chen MT; Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Collaborative Innovation Center of Cancer Medicine, Fudan University Shanghai Cancer Center, Shanghai, 200030, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200030, China.
    Yang LP; Department of pathology, School of Basic Medical Sciences, Fudan University, Shanghai, 200030, China.
    Jin W; Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Collaborative Innovation Center of Cancer Medicine, Fudan University Shanghai Cancer Center, Shanghai, 200030, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200030, China.
  • Oncotarget [Oncotarget] 2017 May 26; Vol. 8 (41), pp. 69680-69690. Date of Electronic Publication: 2017 May 26 (Print Publication: 2017).
  • English
  • To investigate the clinicopathological characteristics and survival outcomes of breast cancer in the male population, 8,607 cases of patients were identified in the Surveillance, Epidemiology, and End Results (SEER) database, including white males ( n = 7122), black males ( n = 1111), and other males (American Indian/AK Native, Asian/Pacific Islander) ( n = 374). Black male breast cancer patients were more likely to be in stages II-IV and have more advanced tumors. The rate of lymph node (LN) involvement at diagnosis was higher in black men than in whites and others. The ER- and PR-positive rates were lower in black men than in whites and others. The distant metastasis rate was higher in blacks than in whites and others. Furthermore, the overall survival (OR) rates and breast cancer-specific survival rates were significantly poorer in blacks than in whites and others (χ 2 = 29.974, P < 0.001; χ 2 = 7.285, P = 0.026, respectively). In a multivariate analysis, the results showed that race could also be a prognostic indicator ( P < 0.001). Moreover, significant differences were also observed in OS among 1:1:1 matched white, black, and other groups ( P < 0.001). Differences in outcomes may be partially explained by differences in tumor grades, LN status, and ER and PR status between the 3 groups. This study might provide insights into a better understanding of male breast cancer.
    Competing Interests: CONFLICTS OF INTEREST The authors declare no conflicts of interest.
Additional Information
Publisher: Impact Journals Country of Publication: United States NLM ID: 101532965 Publication Model: eCollection Cited Medium: Internet ISSN: 1949-2553 (Electronic) Linking ISSN: 19492553 NLM ISO Abbreviation: Oncotarget Subsets: PubMed not MEDLINE
Original Publication: Albany, N.Y. : Impact Journals
Crit Rev Oncol Hematol. 2010 Feb;73(2):141-55. (PMID: 19427229)
Breast J. 2009 Nov-Dec;15(6):593-602. (PMID: 19764994)
Ann Oncol. 2013 Nov;24 Suppl 8:viii75-viii82. (PMID: 24131976)
J Am Coll Surg. 2010 Jul;211(1):105-13. (PMID: 20610256)
Future Oncol. 2010 Jun;6(6):985-91. (PMID: 20528235)
Acta Med Croatica. 1997;51(3):129-33. (PMID: 9248109)
Clin Radiol. 1983 Nov;34(6):625-8. (PMID: 6673881)
Breast Cancer Res. 2011 Sep 29;13(5):219. (PMID: 22017761)
Exp Oncol. 2013 Dec;35(4):303-10. (PMID: 24382442)
Ann Intern Med. 2002 Oct 15;137(8):678-87. (PMID: 12379069)
Cancer. 2013 May 1;119(9):1611-7. (PMID: 23341341)
CA Cancer J Clin. 2013 Jan;63(1):11-30. (PMID: 23335087)
Breast Cancer Res Treat. 2009 May;115(2):429-30. (PMID: 18478326)
Am J Mens Health. 2011 Sep;5(5):430-7. (PMID: 21411477)
Cancer. 1994 Jul 1;74(1):74-7. (PMID: 8004585)
Ann Surg. 1992 May;215(5):451-7; discussion 457-9. (PMID: 1319699)
Int J Cancer. 2013 Apr 15;132(8):1918-26. (PMID: 22987302)
Cancer. 2012 Jan 15;118(2):469-77. (PMID: 21751191)
Breast Cancer Res Treat. 2015 Oct;153(3):679-87. (PMID: 26409835)
J Clin Oncol. 2007 Mar 20;25(9):1089-98. (PMID: 17369572)
Cancer Causes Control. 2013 Sep;24(9):1705-15. (PMID: 23775026)
Lancet. 2006 Feb 18;367(9510):595-604. (PMID: 16488803)
JAMA. 2006 Jun 7;295(21):2492-502. (PMID: 16757721)
Keywords: SEER; male breast cancer; overall survival; race
Date Created: 20171021 Latest Revision: 20220408
20221216
PMC5642508
10.18632/oncotarget.18265
29050233
sponsored